3 ms·
May be not. > The new evidence shows that protective antibodies generated in response to an mRNA vaccine will target a broader range of SARS-CoV-2 variants car
by tchalla 5y ago
May be not.
> The new evidence shows that protective antibodies generated in response to an mRNA vaccine will target a broader range of SARS-CoV-2 variants carrying “single letter” changes in a key portion of their spike protein compared to antibodies acquired from an infection.
https://directorsblog.nih.gov/2021/06/22/how-immunity-generated-from-covid-19-vaccines-differs-from-an-infection/ https://directorsblog.nih.gov/2021/06/22/how-immunity-genera...
- acituan 5y agoYou can’t compare a longitudinal study with a cross sectional study. This study doesn’t account for the time dependent decay of vaccines’ immunity. There is more than one dimension to optimize for.
- mikem170 5y agoSame source you quoted also says: >Our findings show that most COVID-19 patients induce a wide-ranging immune defense against SARS-CoV-2 infection, encompassing antibodies and memory B cells recognizing both the RBD and other regions of the spike, broadly-specific and polyfunctional CD4+ T cells, and polyfunctional CD8+ T cells. Meaning that natural immunity may be better, because it targets not just the spike protein like the vaccine, but also other parts of the virus.